Home    Back

Velcade*1fl 3,5mg    (DrugBank: -)

1 disease
IDDisease name (Link within this page)Number of trials
28Systemic amyloidosis1

28. Systemic amyloidosis    [ 212 clinical trials,   234 drugs,   (DrugBank: 72 drugs),   54 drug target genes,   170 drug target pathways]
Searched query = "Systemic amyloidosis", "AL amyloidosis", "Immunoglobulin light chain amyloidosis", "Amyloid light-chain amyloidosis", "Familial amyloidosis", "Familial amyloid polyneuropathy", "Senile transthyretin amyloidosis", "Senile TTR amyloidosis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 212 trial found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1EUCTR2004-004871-12-IT
(EUCTR)		02/05/200507/06/2005An Open-Label Phase 1/2 Study of VELCADE (bortezomib) for Injection in Subjects with Light-Chain (AL)-AmyloidosisAn Open-Label Phase 1/2 Study of VELCADE (bortezomib) for Injection in Subjects with Light-Chain (AL)-Amyloidosis Systemic AL-Amyloidosis
MedDRA version: 6.1;Level: PT;Classification code 10002022		Trade Name: VELCADE*1FL 3,5MG
Product Name: NA
Product Code: NA
INN or Proposed INN: Bortezomib		JANSSEN-CILAGNULLNot RecruitingFemale: yes
Male: yes		Phase 1;Phase 2Italy